Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blonanserin monotherapy in schizophrenia (open-label, multi-center, Phase 4)
KCT0001105Phase 4Recruiting
- Sponsor
- Bukwang Pharmaceutical
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of blonanserin in schizophrenia, sponsored by Bukwang Pharmaceutical. Started Jun 2013; status: recruiting.
02
Drugs
blonanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on KCT0001105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001105.